相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Renal carcinoma pharmacogenomics and predictors of response: Steps toward treatment individualization
Jesus Garcia-Donas et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2015)
Markers of systemic inflammation predict survival in patients with advanced renal cell cancer
P. Fox et al.
BRITISH JOURNAL OF CANCER (2013)
Interleukin-4 Induces Senescence in Human Renal Carcinoma Cell Lines through STAT6 and p38 MAPK
Hag Dong Kim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Comprehensivemolecular characterization of clear cell renal cell carcinoma
Chad J. Creighton et al.
NATURE (2013)
Cyclooxygenase-2 Expression and Its Prognostic Significance in Clear Cell Renal Cell Carcinoma
Ji Won Lee et al.
KOREAN JOURNAL OF PATHOLOGY (2012)
Modulation of Akt/mTOR Signaling Overcomes Sunitinib Resistance in Renal and Prostate Cancer Cells
Peter B. Makhov et al.
MOLECULAR CANCER THERAPEUTICS (2012)
A common single-nucleotide polymorphism in cyclooxygenase-2 disrupts microRNA-mediated regulation
A. E. Moore et al.
ONCOGENE (2012)
Tumor-Associated Macrophages Mediate Immunosuppression in the Renal Cancer Microenvironment by Activating the 15-Lipoxygenase-2 Pathway
Irina Daurkin et al.
CANCER RESEARCH (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Cyclooxygenase-2 in oncogenesis
Maria Teresa Rizzo
CLINICA CHIMICA ACTA (2011)
Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1
Martha L. Slattery et al.
CARCINOGENESIS (2010)
TNF superfamily gene polymorphism as prognostic factor in early breast cancer
Jin Hyang Jung et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2010)
Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer
L. Quaye et al.
BRITISH JOURNAL OF CANCER (2009)
Prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) 8473T>C polymorphism associated with prognosis for patients with colorectal cancer treated with capecitabine and oxaliplatin
Jong Gwang Kim et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study
Daniel Y. C. Heng et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Endogenous Interleukin-4 Promotes Tumor Development by increasing Tumor Cell Resistance to Apoptosis
Zhiguang Li et al.
CANCER RESEARCH (2008)
Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review
Kiran Gupta et al.
CANCER TREATMENT REVIEWS (2008)
Interleukin-4 promoter polymorphisms: A genetic prognostic factor for survival in metastatic renal cell carcinoma
Thomas Kleinrath et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sunitinib: From rational design to clinical efficacy
Laura Q. M. Chow et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cyclooxygenase-2 expression and relationship to tumour progression in human renal cell carcinoma
Y Hashimoto et al.
HISTOPATHOLOGY (2004)
Impact of cyclooxygenase-2 gene expression on tumor invasiveness in a human renal cell carcinoma cell line
QZ Chen et al.
JOURNAL OF UROLOGY (2004)
Expression of transforming growth factor β in renal cell carcinoma and matched non-involved renal tissue
D Mitropoulos et al.
UROLOGICAL RESEARCH (2004)
Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Association between IL-4 genotype and IL-4 production in the Japanese population
H Nakashima et al.
GENES AND IMMUNITY (2002)